Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Future Oncol
; 17(31): 4091-4099, 2021 Nov.
Article
em En
| MEDLINE
| ID: mdl-34254526
ABSTRACT
Aim:
This study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) plus anlotinib versus anlotinib alone to provide guidance for clinical treatment of non-small-cell lung cancer. Patients &methods:
The records of 139 patients with advanced non-small-cell lung cancer who received at least one dose of ICIs plus anlotinib (IA group) or single-agent anlotinib (AA group) were retrospectively reviewed. The efficacy of the treatments, survival outcomes and adverse events were analyzed. The primary end point was investigator-assessed progression-free survival (PFS).Result:
The IA group had a significantly prolonged median PFS (mPFS 5.8 vs 4.2 months; p = 0.022) compared with the AA group (hazard ratio 0.68; 95% CI 0.68-0.97). In patients with brain metastases, the IA group exhibited improved efficacy (mPFS 6.0 vs 3.8 months; p = 0.034) compared with the AA group (hazard ratio 0.49; 95% CI 0.23-1.05).Conclusion:
ICIs plus anlotinib significantly improved efficacy compared with anlotinib alone and showed substantial potential for the control of intracranial lesions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinolinas
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Checkpoint Imunológico
/
Indóis
/
Neoplasias Pulmonares
Tipo de estudo:
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article